Affordable Access

deepdyve-link
Publisher Website

Association Between Soluble Receptor for Advanced Glycation End Product and Endogenous Secretory Soluble Receptor for Advanced Glycation End Product Levels and Carotid Atherosclerosis in Diabetes: A Systematic Review and Meta-Analysis.

Authors
  • Wang, Xiaofeng1
  • Wang, Qi2
  • Wei, Donghui3
  • Chang, Xiaolong4
  • 1 Department of Neurosurgery, Weinan Central Hospital, Weinan, Shaanxi Province, People's Republic of China. , (China)
  • 2 Department of Ultrasound Diagnosis, Weinan Maternal and Child Health Hospital, Weinan, Shaanxi Province, People's Republic of China. , (China)
  • 3 Department of Neurosurgery, Weinan Central Hospital, Weinan, Shaanxi Province, People's Republic of China. Electronic address: [email protected] , (China)
  • 4 Department of Neurology, First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, People's Republic of China. , (China)
Type
Published Article
Journal
Canadian journal of diabetes
Publication Date
Oct 01, 2021
Volume
45
Issue
7
Pages
634–640
Identifiers
DOI: 10.1016/j.jcjd.2021.01.004
PMID: 33773934
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

The soluble receptor for advanced glycation end product (sRAGE) and endogenous secretory RAGE (esRAGE) are novel biomarkers that are associated with vascular disease. We carried out a systematic review to provide a more complete picture of sRAGE, esRAGE, carotid atherosclerosis and cardiovascular disease (CVD) in patients with diabetes. We searched the Cochrane Library, PubMed and Embase databases. Systematic review best practices were followed, and study quality was assessed. Ultimately, 11 studies met all the inclusion criteria. Meta-analysis indicated that esRAGE was not significantly lower in patients with type 1 diabetes (T1D) (standardized mean difference [SMD], -0.76; 95% confidence interval [CI], -1.57 to 0.05; I2=90%; p=0.002), whereas it was significantly lower in patients with type 2 diabetes (T2D) (SMD, -1.08; 95% CI, -1.53 to -0.62; I2=80%; p=0.006). Meta-analysis suggested that sRAGE levels were not significantly lower or higher in T1D (SMD, 0.06; 95% CI, -0.14 to 0.26; I2=38%; p=0.20) or T2D (SMD, 0.00; 95% CI, -0.26 to 0.26; I2=0.00%; p=1.00) patients. The level of esRAGE was inversely correlated with carotid intima-media thickness (IMT) in T2D patients, whereas there was a contrasting relationship between sRAGE and carotid IMT in T1D patients. Higher sRAGE was associated with cardiovascular events. Our meta-analysis showed that circulating esRAGE was lower and inversely correlated with IMT in T2D patients. Copyright © 2021 Canadian Diabetes Association. Published by Elsevier Inc. All rights reserved.

Report this publication

Statistics

Seen <100 times